NCT01248949 · OUTCOME

Circulating Levels of Angiopoietin 2 (Ang2)

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors · Source last updated 2017-03-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: nanogram per millileter (ng/mL)
Interval / dispersion: Standard Deviation
Time frame: Prior to infusion on Cycle 4 and Cycle 5

What was measured

Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.

Analysis population: All participants who received treatment with MEDI3617 and for whom PD blood samples were collected and evaluated.

Groups in this outcome

MEDI3617 SINGLE AGENT TOTAL

Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.

MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL

Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.

MEDI3617 + BEVACIZUMAB Q2W TOTAL

Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.

MEDI3617 + PACLITAXEL TOTAL

Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.

MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL

Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
MEDI3617 SINGLE AGENT TOTAL	14
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	11
MEDI3617 + BEVACIZUMAB Q2W TOTAL	7
MEDI3617 + PACLITAXEL TOTAL	3
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	2

Reported measurements

Cycle 4: Cohort -2 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	4.07	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.

Cycle 5: Cohort -2 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	4.28	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort -2 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort -1 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	5.11	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort -1 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort 1 (n=3)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	5.69	4.02	Not reported	Not reported	Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.

Cycle 5: Cohort 1 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	8.22	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 1 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort 2 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	307.53	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.

Cycle 5: Cohort 2 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	924.66	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 2 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort 3 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	341.21	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.

Cycle 5: Cohort 3 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	265.86	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 3 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort 4 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	288.10	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 4 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 4 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 4 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 4 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort 5 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	1181.14	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.

Cycle 5: Cohort 5 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	1451.43	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort 5 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort OCE -1 (n=3)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	312.27	151.19	Not reported	Not reported	Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.

Cycle 5: Cohort OCE -1 (n=3)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	206.43	83.74	Not reported	Not reported	Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort OCE -1 was part of the MEDI3617 Single agent total group.

Cycle 4: Cohort MB 1A (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	386.13	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 5: Cohort MB 1A (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	421.74	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 4: Cohort MB 2A (n=3)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	215.71	143.16	Not reported	Not reported	Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 5: Cohort MB 2A (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	228.92	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 4: Cohort MB 3A (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	218.48	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 5: Cohort MB 3A (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	247.51	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 4: Cohort MB 4A (n=4)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	368.08	257.59	Not reported	Not reported	Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 5: Cohort MB 4A (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	353.73	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.

Cycle 4: Cohort MB 1B (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	466.27	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 5: Cohort MB 1B (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	750.61	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 4: Cohort MB 2B (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	421.03	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 5: Cohort MB 2B (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	387.45	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 4:Cohort MB 3B (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	141.93	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 4: Cohort MB 4B (n=3)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	229.19	109.02	Not reported	Not reported	Not reported
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 5: Cohort MB 4B (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	174.65	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.

Cycle 4: Cohort MP1 (n=1)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + PACLITAXEL TOTAL	339.35	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MP1 was part of the MEDI3617 + Paclitaxel group.

Cycle 4: Cohort MP2 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + PACLITAXEL TOTAL	210.43	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.

Cycle 5: Cohort MP2 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
MEDI3617 + PACLITAXEL TOTAL	166.73	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MP2 was part of the MEDI3617 + Paclitaxel group.

Cycle 4: Cohort MCP1 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	348.53	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).

Cycle 5: Cohort MCP1 (n=2)

Values in nanogram per millileter (ng/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
MEDI3617 SINGLE AGENT TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + BEVACIZUMAB Q2W TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + PACLITAXEL TOTAL	NA	NA	Not reported	Not reported	Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL	336.31	NA	Not reported	Not reported	Standard deviation was not calculated due to limited sample size (n\<3).

Complete source fields

classes

categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
4.07
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort -2 (n=2)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
4.28
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort -2 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 5: Cohort -2 (n=2)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
5.11
comment
Cohort -1 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort -1 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort -1 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort -1 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort -1 (n=2)
categories
measurements
group Id
OG000
spread
4.02
value
5.69
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort 1 (n=3)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
8.22
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 1 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 5: Cohort 1 (n=2)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
307.53
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort 2 (n=1)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
924.66
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 2 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 5: Cohort 2 (n=1)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
341.21
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort 3 (n=1)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
265.86
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 3 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 5: Cohort 3 (n=1)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
288.10
comment
Cohort 4 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 4 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 4 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 4 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort 4 (n=1)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
1181.14
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 4: Cohort 5 (n=1)
categories
measurements
comment
Standard deviation was not calculated due to limited sample size (n\<3).
group Id
OG000
spread
NA
value
1451.43
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG001
spread
NA
value
NA
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG002
spread
NA
value
NA
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG003
spread
NA
value
NA
comment
Cohort 5 was part of the MEDI3617 Single agent total group.
group Id
OG004
spread
NA
value
NA
title
Cycle 5: Cohort 5 (n=1)

denoms

counts
group Id
OG000
value
14
group Id
OG001
value
11
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
2
units
Participants

description

Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.

dispersion Type

Standard Deviation

groups

description
Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
id
OG000
title
MEDI3617 SINGLE AGENT TOTAL
description
Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
id
OG001
title
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
description
Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
id
OG002
title
MEDI3617 + BEVACIZUMAB Q2W TOTAL
description
Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
id
OG003
title
MEDI3617 + PACLITAXEL TOTAL
description
Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
id
OG004
title
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL

param Type

MEAN

population Description

All participants who received treatment with MEDI3617 and for whom PD blood samples were collected and evaluated.

reporting Status

POSTED

time Frame

Prior to infusion on Cycle 4 and Cycle 5

title

Circulating Levels of Angiopoietin 2 (Ang2)

type

SECONDARY

unit Of Measure

nanogram per millileter (ng/mL)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice